Trials / Completed
CompletedNCT01394458
Efficacy and Safety of an Ethanol/Sodium Citrate Locking Solution: A Pilot Study
Efficacy and Safety of an Ethanol/Sodium Citrate Locking Solution to Prevent Hemodialysis Catheter-Related Infections: A Pilot Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- University of Manitoba · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Currently in Canada, either 4% sodium citrate or heparin 1,000-10,000 U/ml solutions are "locked" into hemodialysis catheters between dialysis sessions to prevent thrombosis. The use of an ethanol/sodium citrate locking solution may have advantages over either of these agents alone. The investigators hypothesize that the 30 % ethanol/4% sodium citrate catheter locking solution is safe and effective in the prevention of catheter-related infections and thrombosis.
Detailed description
The pilot study will utilize a prospective, randomized design. After meeting the inclusion/exclusion criteria and providing written informed consent, patients will be randomly assigned to a 30 % ethanol/ 4% sodium citrate locking solution or heparin 1000 U/ml. Patients will be enrolled from the Health Sciences Centre and the Sherbrook Dialysis Units in Winnipeg, Manitoba, Canada.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | 30 % ethanol / 4% sodium citrate catheter locking solution | This solution is locked into the lumens of hemodialysis catheters between treatments to prevent infection and thrombosis. Before each dialysis session, the solution should be removed and discarded. |
| DRUG | Heparin 1000 u / ml | In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session. |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2011-07-14
- Last updated
- 2015-12-04
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01394458. Inclusion in this directory is not an endorsement.